Table 1 Clinical characteristics of n = 19 consecutive patients treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma.
From: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
median age (range) at time of HFSRT | 50 years | (11–74 years) |
|---|---|---|
male / female | 8 (42%)/11(58%) | |
median Karnofsky performance score at time of HFSRT (range) | 90 | (60–90) |
initial histology | ||
astrocytoma II° | 3 (16%) | |
pure anaplastic astrocytoma III° | 4 (21%) | |
anaplastic oligoastrocytoma or oligodendroglioma III° | 3 (16%) | |
glioblastoma multiforme IV° | 9 (47%) | |
most recent histology before HFSRT | ||
anaplastic astrocytoma III° | 5 (26%) | |
glioblastoma multiforme IV° | 14 (74%) | |
initial surgical procedure | ||
resection | 15 (79%) | |
biopsy | 4 (21%) | |
post-operative radiotherapy | ||
1.8–2.0 Gy daily (total dose 54 to 61 Gy) | 12 (63%) | |
3 Gy daily (total dose 45 Gy) | 2 (11%) | |
2 × 1.8 Gy daily (total dose 54 Gy) | 5 (26%) | |
salvage surgery before HFSRT | 12 (63%) | |
adjuvant or salvage chemotherapy before HFSRT | ||
nimustine / teniposide | 12 (63%) | |
temozolomide | 5 (26%) | |
other | 1 (5%) | |
median interval post-OP radiotherapy to HFSRT (range) | 19 months | (3–116 months) |